Key Highlights
- Amgen (NASDAQ:AMGN) shows USD 478.48 on the all-time-high screen, up 3.73% in the November 4, 2026 session, with relative Volume of 1.75 and a Market Value of about USD 258.68 billion. Screen figures are unverified.
- Third-quarter 2026 revenue, released after the close on November 3, rose 8% to USD 10.4 billion, and non-GAAP EPS rose 14% to USD 6.45.
- The 2026 Revenue guide rose to USD 38.9 billion to USD 39.7 billion from USD 38.2 billion to USD 39.4 billion, and non-GAAP EPS guidance rose to USD 22.90 to USD 23.70.
- Repatha sales rose 37% to USD 1,085 million, EVENITY rose 39% and TEZSPIRE rose 43%, more than offsetting biosimilar erosion in Prolia and XGEVA.
What Drove the Record
The 3.73% gain was a direct response to results released the previous evening. Amgen (NASDAQ:AMGN) reported third-quarter product sales of USD 9,883 million, up 8% and driven by volume rather than price. GAAP EPS rose 19% to USD 7.08 and non-GAAP EPS rose 14% to USD 6.45. Management raised both ends of its full-year revenue range by USD 0.7 billion and both ends of its non-GAAP EPS range by USD 0.60. The growth came from a broad set of products. Repatha, the cholesterol drug, reached USD 1,085 million. EVENITY for osteoporosis reached USD 751 million, TEZSPIRE for asthma USD 538 million and BLINCYTO for leukemia USD 496 million. Newer launches grew faster: IMDELLTRA rose 128% to USD 406 million and UPLIZNA rose 191% to USD 451 million. That breadth matters because it shows growth is not tied to one product. Total revenue, including other revenue, was USD 10.4 billion, up 8% from the same quarter a year earlier. GAAP Operating Margin rose to 37.5%, a gain of 9.9 points.
Why the Record Holds More Than One Quarter
Amgen is managing a known headwind. Prolia sales fell 45% to USD 632 million and XGEVA fell 47% to USD 288 million as Biosimilars took share, and the company still grew total product sales 8%. A record high reached while absorbing that erosion signals that investors see the growth portfolio as large enough to carry the company. The obesity program adds a longer-dated reason. MariTide has several Phase 3 studies under way, with studies in cardiovascular disease, obesity and sleep apnea having completed enrollment and weight management studies ongoing. Results are not due in this quarter, but the program supports a higher multiple. The screen shows a trailing P/E of 27.75 on EPS of USD 17.24 and EPS growth of 33.31%, unverified. The quarterly Dividend is USD 2.52 per share, up 6% from a year earlier. The company has set a ceiling of USD 3.0 billion on 2026 share repurchases, which gives it room to return more cash later in the year.
Risks and What to Watch
Free Cash Flow fell to USD 3.7 billion from USD 4.2 billion because of Working Capital changes, a number to watch in the fourth quarter. Debt stands at USD 54.0 billion against cash of USD 13.2 billion, and no shares were repurchased in the quarter. Drug pricing policy is a sector risk, and the November 5 market sell-off, the worst since April 2025, shows how fast sentiment can change. Investors in Amgen (NASDAQ:AMGN) should watch MariTide trial updates, the pace of Prolia and XGEVA erosion, and whether volume-driven growth near 8% holds into 2027. Capital spending is expected to be about USD 2.6 billion in 2026, which supports Manufacturing capacity for newer drugs.
Where Things Stand
Amgen reached an all-time high after a 3.73% rise on third-quarter revenue of USD 10.4 billion, volume-led product growth of 8% and a raised 2026 outlook. Strong growth in Repatha, EVENITY, TEZSPIRE and new launches more than offset biosimilar losses. Lower free cash flow, high debt and pricing policy are the main risks.






Please wait processing your request...